Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 4/20 | 0.47 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.47 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7043317 | 0.92 | CHRNA7 (0.45) | CHRNA7CHRNB2CHRNA4ALDH1A1POLB | |
| SCHEMBL7042267 | 0.91 | TDP1 (0.44) | CHRNA7CHRNB2CHRNA4ALDH1A1POLB | |
| SCHEMBL372881 | 0.86 | CHRNA7 (0.56) | CHRNA7CHRNB2CHRNA4ALDH1A1POLB | |
| SCHEMBL31375366 | 0.86 | CHRNA7 (0.56) | CHRNA7CHRNB2CHRNA4ALDH1A1POLB | |
| SCHEMBL372987 | 0.86 | CHRNA7 (0.56) | CHRNA7CHRNB2CHRNA4ALDH1A1POLB | |
| Hydrochloric Acid SCHEMBL373321 | 0.85 | LMNA (0.55) | CHRNA7CHRNB2CHRNA4ALDH1A1POLB | |
| SCHEMBL7043759 | 0.78 | CHRNA7 (0.53) | CHRNA7CHRNB2CHRNA4ALDH1A1POLB | |
| SCHEMBL10916764 | 0.74 | ALDH1A1 (0.54) | ALDH1A1POLBCYP2D6LMNACTSK | |
| SCHEMBL9325101 | 0.74 | ALDH1A1 (0.60) | CHRNA7CHRNB2CHRNA4ALDH1A1POLB | |
| SCHEMBL699563 | 0.73 | CHRNA7 (0.74) | CHRNA7CHRNB2CHRNA4SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541447-B2 | 3-substituted-2-(arlyalkyl)-1-azabicycloalkanes and methods of use thereof | TARGACEPT, INC. (US) | 2013-09-24 | — | — | US | disclosed |
| US-20120136024-A1 | 3-Substituted-2-(arlyalkyl)-1-azabicycloalkanes and Methods of Use Thereof | TARGACEPT, INC. (US) | 2012-05-31 | — | — | US | disclosed |
| US-8158649-B2 | 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof | TARGACEPT, INC. (US) | 2012-04-17 | — | — | US | disclosed |
| US-8143272-B2 | 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof | TARGACEPT, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-8124618-B2 | 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof | TARGACEPT, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-8124619-B2 | 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof | TARGACEPT, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-8124620-B2 | 3-Substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof | TARGACEPT, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-8084462-B2 | 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof | TARGACEPT, INC. (US) | 2011-12-27 | — | — | US | disclosed |
| US-20110071187-A1 | 3-SUBSTITUTED-2(ARYLALKYL)-1-AZABICYCLOALKANES AND METHODS OF USE THEREOF | TARGACEPT, INC. (US) | 2011-03-24 | — | — | US | disclosed |
| US-20110071188-A1 | 3-SUBSTITUTED-2(ARYLALKYL)-1-AZABICYCLOALKANES AND METHODS OF USE THEREOF | TARGACEPT, INC. (US) | 2011-03-24 | — | — | US | disclosed |
| US-20060247270-A1 | e.g. 2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl N-phenylcarbamate; nicotinic acetylcholine receptors alpha 7 (nAChRs)/neurotransmitter modulator; diagnostic radiolabel; central nervous systrem disorders, autoimmune diseases; antiinflammatory, antitumor agents, angiogenesis inhibitor | ATTENUA, INC. | 2006-11-02 | — | — | US | disclosed |
| US-20050255040-A1 | 3-Substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof | ATTENUA, INC. | 2005-11-17 | — | — | US | disclosed |
| EP-1594869-A2 | 3-SUBSTITUTED-2(ARYLALKYL)-1-AZABICYCLOALKANES AND METHODS OF USE THEREOF | Targacept, Inc. (US) | 2005-11-16 | — | — | EP | disclosed |
| US-6953855-B2 | 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof | TARGACEPT, INC. (US) | 2005-10-11 | — | — | US | disclosed |
| WO-2004076449-A2 | 3-SUBSTITUTED-2(ARYLALKYL)-1-AZABICYCLOALKANES AND METHODS OF USE THEREOF | TARGACEPT, INC. (US) | 2004-09-10 | — | — | WO | disclosed |
| US-20040002513-A1 | 3-Substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof | ATTENUA, INC. | 2004-01-01 | — | — | US | disclosed |
| US-20030045523-A1 | Nicotinic cholinergic receptor antagonists | SCHMITT JEFFREY DANIEL (US) | 2003-03-06 | — | — | US | disclosed |
| US-6432975-B1 | AROMATIC ALKYLENE AZOBICYCLIC COMPOUNDS AS NICOTINIC RECEPTOR ANTAGONISTS; ANTIDEPRESSANTS; NERVOUS SYSTEM DISORDER TREATMENT | TARGACEPT, INC. | 2002-08-13 | — | — | US | disclosed |
| EP-1053236-A1 | PYRDIYL-BRIIDGEHEAD DERIVATIVES AND THEIR ANALOGUES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE AS INHIBITORS OF NICOTINIC CHOLINERGIC RECEPTORS | R.J. REYNOLDS TOBACCO COMPANY (US) | 2000-11-22 | — | — | EP | disclosed |
| WO-2000034276-A1 | PYRIDYL-BRIDGEHEAD DERIVATIVES AND THEIR ANALOGUES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE AS INHIBITORS OF NICOTINIC CHOLINERGIC RECEPTORS | R.J. REYNOLDS TOBACCO COMPANY (US) | 2000-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110071187-A1 | 3-SUBSTITUTED-2(ARYLALKYL)-1-AZABICYCLOALKANES AND METHODS OF USE THEREOF | CHRNA7, CHRNA3, CHRNA5 | CHRNA7 1/4885CHRNB2 15/4885CHRNA4 10/4885 |
| US-20030045523-A1 | Nicotinic cholinergic receptor antagonists | CHRNG, CHRNB1, CHRNA1 | CHRNA7 11/4885CHRNB2 9/4885CHRNA4 13/4885 |
| US-20060247270-A1 | e.g. 2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl N-phenylcarbamate; nicotinic acetylcholine receptors alpha 7 (nAChRs)/neurotransmitter modulator; diagnostic radiolabel; central nervous systrem disorders, autoimmune diseases; antiinflammatory, antitumor agents, angiogenesis inhibitor | CHRM1, CHRNA7, CHRM3 | CHRNA7 2/4885CHRNB2 22/4885CHRNA4 16/4885 |
| US-20120136024-A1 | 3-Substituted-2-(arlyalkyl)-1-azabicycloalkanes and Methods of Use Thereof | CHRNA7, CHRNA1, CHRNA3 | CHRNA7 1/4885CHRNB2 14/4885CHRNA4 11/4885 |
| US-20110071188-A1 | 3-SUBSTITUTED-2(ARYLALKYL)-1-AZABICYCLOALKANES AND METHODS OF USE THEREOF | CHRNA7, CHRNA5, CHRNA3 | CHRNA7 1/4885CHRNB2 19/4885CHRNA4 11/4885 |
| US-20040002513-A1 | 3-Substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof | CHRNA7, CHRNA3, CHRNA1 | CHRNA7 1/4885CHRNB2 14/4885CHRNA4 10/4885 |
| US-20050255040-A1 | 3-Substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof | CHRNA7, CHRNA3, CHRNA5 | CHRNA7 1/4885CHRNB2 15/4885CHRNA4 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.